189 related articles for article (PubMed ID: 37845471)
21. LOT and HOT … or not. The proliferation of clinically insignificant and poorly characterised types of renal neoplasia.
Samaratunga H; Egevad L; Thunders M; Iczskowski KA; van der Kwast T; Kristiansen G; Pan CC; Leite KRM; Evans A; Clouston D; Kenwright DN; Bethwaite PB; Malone G; Wood S; Yaxley JW; Delahunt B
Pathology; 2022 Dec; 54(7):842-847. PubMed ID: 36270849
[TBL] [Abstract][Full Text] [Related]
22. [Eosinophilic vacuolated tumor of the kidney: clinicopathological and molecular characteristics].
Zhang HZ; Xia QY; Yin XG; Wang SY
Zhonghua Bing Li Xue Za Zhi; 2022 May; 51(5):437-443. PubMed ID: 35511640
[No Abstract] [Full Text] [Related]
23. Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
Roldan-Romero JM; Santos M; Lanillos J; Caleiras E; Anguera G; Maroto P; García-Donas J; de Velasco G; Martinez-Montes ÁM; Calsina B; Monteagudo M; Letón R; Leandro-García LJ; Montero-Conde C; Cascón A; Robledo M; Rodriguez-Antona C
Mod Pathol; 2020 Dec; 33(12):2580-2590. PubMed ID: 32616874
[TBL] [Abstract][Full Text] [Related]
24. GPNMB expression identifies TSC1/2/mTOR-associated and MiT family translocation-driven renal neoplasms.
Salles DC; Asrani K; Woo J; Vidotto T; Liu HB; Vidal I; Matoso A; Netto GJ; Argani P; Lotan TL
J Pathol; 2022 Jun; 257(2):158-171. PubMed ID: 35072947
[TBL] [Abstract][Full Text] [Related]
25. mTOR eosinophilic renal cell carcinoma: a distinctive tumor characterized by mTOR mutation, loss of chromosome 1, cathepsin-K expression, and response to target therapy.
Caliò A; Marletta S; Settanni G; Rizzo M; Gobbo S; Pedron S; Stefanizzi L; Munari E; Brunelli M; Marcolini L; Pesci A; Fratoni S; Pierconti F; Raspollini MR; Marchetti A; Doglioni C; Amin MB; Porta C; Martignoni G
Virchows Arch; 2023 Dec; 483(6):821-833. PubMed ID: 37938323
[TBL] [Abstract][Full Text] [Related]
26. Low-grade oncocytic tumor (LOT) - a new renal entity ready for a prime time: An updated review.
Mansoor M; Siadat F; Trpkov K
Histol Histopathol; 2022 May; 37(5):405-413. PubMed ID: 35156688
[TBL] [Abstract][Full Text] [Related]
27. Characterization of a distinct low-grade oncocytic renal tumor (CD117-negative and cytokeratin 7-positive) based on a tertiary oncology center experience: the new evidence from China.
Guo Q; Liu N; Wang F; Guo Y; Yang B; Cao Z; Wang Y; Wang Y; Zhang W; Huang Q; Zhao W; Liu C; Qu T; Li L; Cao L; Ren D; Meng B; Qi L; Wang C; Cao W
Virchows Arch; 2021 Mar; 478(3):449-458. PubMed ID: 32918598
[TBL] [Abstract][Full Text] [Related]
28. Low-Grade Oncocytic Tumor of Kidney (CK7-Positive, CD117-Negative): Incidence in a single institutional experience with clinicopathological and molecular characteristics.
Kravtsov O; Gupta S; Cheville JC; Sukov WR; Rowsey R; Herrera-Hernandez LP; Lohse CM; Knudson R; Leibovich BC; Jimenez RE
Hum Pathol; 2021 Aug; 114():9-18. PubMed ID: 33961838
[TBL] [Abstract][Full Text] [Related]
29. TSC/MTOR mutated renal cell carcinoma with leiomyomatous stroma is a distinct entity: a comprehensive study of 12 cases.
Tjota MY; Sharma A; Wanjari P; Fitzpatrick C; Segal J; Antic T
Hum Pathol; 2023 Apr; 134():124-133. PubMed ID: 36592877
[TBL] [Abstract][Full Text] [Related]
30. TSC/mTOR Pathway Mutation Associated Eosinophilic/Oncocytic Renal Neoplasms: A Heterogeneous Group of Tumors with Distinct Morphology, Immunohistochemical Profile, and Similar Genetic Background.
Pivovarcikova K; Alaghehbandan R; Vanecek T; Ohashi R; Pitra T; Hes O
Biomedicines; 2022 Jan; 10(2):. PubMed ID: 35203531
[TBL] [Abstract][Full Text] [Related]
31. Papillary renal cell carcinoma with cytologic and molecular genetic features overlapping with renal oncocytoma: Analysis of 10 cases.
Michalova K; Steiner P; Alaghehbandan R; Trpkov K; Martinek P; Grossmann P; Montiel DP; Sperga M; Straka L; Prochazkova K; Cempirkova D; Horava V; Bulimbasic S; Pivovarcikova K; Daum O; Ondic O; Rotterova P; Michal M; Hora M; Hes O
Ann Diagn Pathol; 2018 Aug; 35():1-6. PubMed ID: 30072012
[TBL] [Abstract][Full Text] [Related]
32. Sporadic hybrid oncocytic/chromophobe tumor of the kidney: a clinicopathologic, histomorphologic, immunohistochemical, ultrastructural, and molecular cytogenetic study of 14 cases.
Petersson F; Gatalica Z; Grossmann P; Perez Montiel MD; Alvarado Cabrero I; Bulimbasic S; Swatek A; Straka L; Tichy T; Hora M; Kuroda N; Legendre B; Michal M; Hes O
Virchows Arch; 2010 Apr; 456(4):355-65. PubMed ID: 20300772
[TBL] [Abstract][Full Text] [Related]
33. [Eosinophilic, solid, and cystic renal cell carcinoma (ESC-RCC)].
Hartmann A; Agaimy A
Pathologe; 2021 Nov; 42(6):565-570. PubMed ID: 34550432
[TBL] [Abstract][Full Text] [Related]
34. PTEN Expression, Not Mutation Status in
Voss MH; Chen D; Reising A; Marker M; Shi J; Xu J; Ostrovnaya I; Seshan VE; Redzematovic A; Chen YB; Patel P; Han X; Hsieh JJ; Hakimi AA; Motzer RJ
Clin Cancer Res; 2019 Jan; 25(2):506-514. PubMed ID: 30327302
[TBL] [Abstract][Full Text] [Related]
35. "High-grade oncocytic renal tumor": morphologic, immunohistochemical, and molecular genetic study of 14 cases.
He H; Trpkov K; Martinek P; Isikci OT; Maggi-Galuzzi C; Alaghehbandan R; Gill AJ; Tretiakova M; Lopez JI; Williamson SR; Montiel DP; Sperga M; Comperat E; Brimo F; Yilmaz A; Pivovarcikova K; Michalova K; Slouka D; Prochazkova K; Hora M; Bonert M; Michal M; Hes O
Virchows Arch; 2018 Dec; 473(6):725-738. PubMed ID: 30232607
[TBL] [Abstract][Full Text] [Related]
36. Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.
Ghosh AP; Marshall CB; Coric T; Shim EH; Kirkman R; Ballestas ME; Ikura M; Bjornsti MA; Sudarshan S
Oncotarget; 2015 Jul; 6(20):17895-910. PubMed ID: 26255626
[TBL] [Abstract][Full Text] [Related]
37. Low-Grade Oncocytic Tumor: Report of Two Cases of An Emerging Entity in the Spectrum of Oncocytic Renal Neoplasms.
Sharma D; Pai T; Prakash G; Desai S; Menon S
Turk Patoloji Derg; 2022; 38(2):162-166. PubMed ID: 34514579
[TBL] [Abstract][Full Text] [Related]
38. Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma.
Kwiatkowski DJ; Choueiri TK; Fay AP; Rini BI; Thorner AR; de Velasco G; Tyburczy ME; Hamieh L; Albiges L; Agarwal N; Ho TH; Song J; Pignon JC; Barrios PM; Michaelson MD; Van Allen E; Krajewski KM; Porta C; Pal S; Bellmunt J; McDermott DF; Heng DYC; Gray KP; Signoretti S
Clin Cancer Res; 2016 May; 22(10):2445-2452. PubMed ID: 26831717
[TBL] [Abstract][Full Text] [Related]
39. Somatic Bi-allelic Loss of TSC Genes in Eosinophilic Solid and Cystic Renal Cell Carcinoma.
Mehra R; Vats P; Cao X; Su F; Lee ND; Lonigro R; Premkumar K; Trpkov K; McKenney JK; Dhanasekaran SM; Chinnaiyan AM
Eur Urol; 2018 Oct; 74(4):483-486. PubMed ID: 29941307
[TBL] [Abstract][Full Text] [Related]
40. Eosinophilic Vacuolated Tumor of the Kidney: A Review of Evolving Concepts in This Novel Subtype With Additional Insights From a Case With MTOR Mutation and Concomitant Chromosome 1 Loss.
Kapur P; Gao M; Zhong H; Rakheja D; Cai Q; Pedrosa I; Margulis V; Xu L; Kinch L; Brugarolas J
Adv Anat Pathol; 2021 Jul; 28(4):251-257. PubMed ID: 34009776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
